Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection

Bhagya D. Navalkele 1
Teena Chopra 2
1 Internal Medicine and Infectious Diseases, University of Mississippi Medical Center, Jackson, MS, USA; 2 Internal Medicine and Infectious Diseases, Infection Prevention and Epidemiology, Detroit Medical Center, Wayne State University, Detroit, MI, USA

Abstract: Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%–35% risk after primary CDI to 35%–65% risk after the first recurrent episode. Recurrent CDI is one of the most challenging and a very difficult to treat infections. Standard guidelines provide recommendations on treatment of primary CDI. However, treatment choices for recurrent CDI are limited. Recent research studies have focused on the discovery of newer alternatives for prevention of recurrent CDI targeting prime virulence factors involved in C. difficile pathogenesis. Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Multiple in vitro and in vivo animal studies have demonstrated direct binding of bezlotoxumab to C. difficile toxin B preventing intestinal epithelial damage and colitis. Furthermore, this monoclonal antibody mediates early reconstitution of gut microbiota preventing risk of recurrent CDI. Randomized placebo-controlled trials showed concomitant administration of a single intravenous dose of 10 mg/kg of bezlotoxumab, in patients on standard-of-care therapy for CDI, had no substantial effect on clinical cure rates but significantly reduced the incidence of recurrent CDI (~40%). It shows efficacy against multiple strains, including the epidemic BI/NAP1/027 strain. Bezlotoxumab is a US Food and Drug administration-approved, safe and well-tolerated drug with low risk of serious adverse events and drug–drug interactions. Bezlotoxumab has emerged as a novel dynamic adjunctive therapy for prevention of recurrent CDI. Further studies on real-world experience with bezlotoxumab and its impact in reducing rates of recurrent CDI are needed.

Keywords: bezlotoxumab, Clostridium difficile, monoclonal antibody, novel CDI treatment, anti-toxin B antibody, prevention of recurrent CDI

Introduction

Clostridium difficile, a spore-forming anaerobic gram-positive bacillus, causes infections ranging from mild diarrhea to severe complicated disease. Clostridium difficile infection (CDI) is recognized as a leading cause of hospital-onset infection. Lately, increasing incidences of CDI are being reported from other settings such as the community, long-term care facilities, and nursing homes.

After the initial episode of CDI, the risk for recurrent infections increases exponentially. Of the nearly 500,000 CDIs in the USA in 2011, approximately 1% developed at least one episode of recurrent CDI. Subsequently, the risk of further recurrences following the first recurrent CDI is estimated to range from 35% to 65%. CDI is associated with varied mortality rates of 3%–36%. On the contrary, recurrent CDI is associated with 33% higher mortality risk and 2.5-fold higher hospital readmission rate.
In 2008, acute care facilities were estimated to spend approximately US$4.8 billion in health care expenditures for the management of hospital-onset-CDI. A model-framework study by Desai et al estimated 87% of CDI expenditure in 2014 (US$4.7 billion) to be related to acute care hospitalizations, long-term acute care, and long-term care facility costs. The study reported lower costs (US$725 million) in the management of CDI in the community. Per study analysis, 33% of the total CDI expenditure in a health care facility is devoted to the management of recurrent CDI (US$1.5/4.7 billion). A retrospective study performed in Canada from 1998 to 2013 reported 9% of CDI patients developed multiple (>2) recurrent CDI (128/1389). In the recurrent CDI subset population (n=434), 34% of patients required hospitalization for the management of recurrent episode. The total cost of hospitalization in patients with recurrent CDI was estimated to be US$6,500 per day. The real-world prevalence of CDI and its related expenditure in the non-acute care setting remains undetermined. Thus, the true health care burden of CDI remains unknown.

The key objectives in management of CDI are clinical cure and prevention of recurrent CDI. Limited management strategies exist to prevent these recurrent episodes. Bezlotoxumab is a novel monoclonal antibody against C. difficile toxin B approved for prevention of recurrent CDI. Here, we provide a detailed review on CDI pathogenesis, the current available CDI treatment options, and on bezlotoxumab outlining its pharmacology, mechanism of action, efficacy data, and safety evidence.

**CDI pathogenesis**

**Bacterial pathogenesis**

Introduction of spores via fecal-oral route is the first step in intestinal colonization and infection with C. difficile. C. difficile spores are infective particles harboring the dormant form of C. difficile bacteria. They play a crucial role in infection and transmission of CDI. C. difficile spores are resistant to heat, radiation, and alcohol-based disinfection resulting in environmental persistence. Fecal shedding of spores by symptomatic and asymptomatic C. difficile carrier patients causes rapid spread of this disease. Spores travel through the stomach into the small intestine where under optimal conditions (higher cholate-containing bile salts and lower chenodeoxycholic acids) germination of spores results in formation of the vegetative cells. These vegetative cells then colonize and proliferate in the colon marking the onset of CDI.

The severe pathogenesis of CDI is regulated by expression of genes located on the pathogenicity locus controlling the major functions of toxin production (toxin A and B genes), toxin expression (toxin R), toxin release (toxin E), and toxin synthesis (toxin C).

Of all the virulence factors attributed to CDI, toxin production is the most significant factor. Non-pathogenic C. difficile strains produce spores but do not cause symptomatic infection in animals or humans. Infection with pathogenic strains results in toxin production from the vegetative cells leading to CDI. Toxin A and toxin B are the two pathogenic toxins involved in CDI. Toxins act by binding to the intestinal epithelial cells, undergoing endocytosis, and then forming pores in the epithelial cells. Toxins also inactivate the Rho proteins, which regulate actin depolymerization and maintain structural integrity of the cell. This inactivation has a cytopathic effect on the colonic wall increasing its permeability and apoptosis leading to diarrhea. Toxin-related cytotoxic effects are seen secondary to activation of inflammatory markers producing colitis and severe CDI. Besides intestinal effects, there is evidence of toxin-mediated extra-intestinal damage causing neurotoxicity, cardiotoxicity, and nephrotoxicity.

Multiple animal studies reported toxin A as the major virulence factor associated with severe inflammatory response and intestinal damage in CDI. Immunization against toxin A, not toxin B, in hamster models was protective against C. difficile colitis. Toxin B was reported to be functionally dependent on toxin A-related intestinal damage to produce cytotoxic effect on intestinal epithelial cells. However, recent numerous animal studies have published the independent pathogenicity of toxin B, now recognized as the major toxin in CDI. Toxin B resulted in higher inflammatory response, severe damage to colonic wall, systemic CDI, and higher mortality in the hamster models compared to toxin A. Thus, most of the ongoing research studies are focused on the discovery of agents targeted against C. difficile toxin B.

Strain typing has led to the identification of numerous geographically and genetically diverse strains of C. difficile. Multiple CDI outbreaks in the low risk population of the USA, UK, and Canada have led to the discovery of hypervirulent strain of C. difficile identified as the BI/NAP1/027 strain. The widespread use of fluoroquinolones was correlated to the rapid spread of this epidemic strain harboring intrinsic fluoroquinolone resistance. The epidemic strains frequently cause severe CDI. This infectious property is secondary to the higher amounts of toxin production by epidemic strains than wild type strains and the production of variant toxin B potentiating its cytotoxicity. Other than the role of toxin A and B in CDI pathogenesis, the binary toxin, C. difficile transferases, has been recognized as an additional virulence factor, especially...
in the BI/NAP1/027 strain. The binary toxin is presumed to aid in adherence and colonization of *C. difficile*. Its complete role in the pathogenesis is still undetermined.

Other non-toxin related virulence factors involved in CDI pathogenesis act by increasing its adhesion to the cell wall. Cell wall proteins, fibronectin-binding proteins, heat-shock proteins found in *C. difficile* and polysaccharides in the vegetative cells, support adhesion of *C. difficile* to the intestinal epithelial cells promoting its colonic invasion and colonization. Fimbriae and flagella in *C. difficile* also aid in adhesion and intestinal colonization, however its exact role remains controversial due to its inconsistent detection in different *C. difficile* isolates.

**Host defense**

Natural host defenses against infection from *C. difficile* are provided by the gut microbiota. However, disruption in the normal gastrointestinal microbiota, predominantly seen after treatment with antibiotic therapy, serves as a foundation for unexpressed *C. difficile* colonization and infection.

During the infective period, humoral immune response is generated against *C. difficile* resulting in the production of endogenous antitoxin antibodies to fight against *C. difficile* toxins A and B. Lower serum antitoxin antibody levels have been linked to the development of severe and recurrent CDI. In humans, use of intravenous antitoxin antibodies has led to suppression of CDI symptoms. Vaccination against toxin A and B in patients with relapsing CDI has successfully reduced the relapse rates. In vitro study on human colonic explants and peripheral blood monocyte cell cultures showed diminished inflammatory response and colonic inflammation in presence of the antitoxin antibody against *C. difficile* toxin A and B. Thus, published research studies have established the crucial role of antitoxin antibodies in protecting against the deleterious effects of CDI.

**Current treatment options for CDI**

Discontinuation of ongoing antibiotic therapy is the best strategy in the treatment of CDI. However, as stopping the antibiotic therapy is not always feasible, specific anti-CDI treatment is recommended in the management of CDI. Metronidazole is the first-line choice in treatment of primary non-severe CDI, however there is growing evidence of higher metronidazole resistance and lower clinical success with metronidazole in comparison to vancomycin. Currently, vancomycin is the preferred oral antibiotic for treatment of both primary and recurrent CDI. Dual antibiotic therapy with metronidazole and vancomycin has been recommended for treatment of severe complicated CDI. Unfortunately, vancomycin and metronidazole have both demonstrated ability to disrupt the colonic microbiota limiting its efficacy in prevention of recurrent CDI. Fidaxomicin is a potent antibiotic therapy option with minimal risk of damage to colonic flora, providing sustained cure rates in CDI. However, weak evidence in treatment of life-threatening disease and high drug cost have limited its application. Multiple newer antibiotics with activity against *C. difficile* are currently under trial.

Substantial evidence supports the use of fecal microbiota transplant (FMT) in prevention of recurrent CDI. The European Society of Clinical Microbiology and Infectious diseases guidelines recommend the use of non-antibiotic therapy of choice for the management of recurrent CDI. Unfortunately, FMT continues to be an experimental procedure awaiting formal recommendation for use in CDI treatment guidelines in the USA.

Apart from treatment options, there has been an increasing focus on prevention of CDI to reduce the health care burden. The use of probiotics in prevention of CDI remains controversial. Multiple randomized controlled trials and meta-analyses studies have demonstrated the potential benefit of probiotics, especially in patients with recurrent CDI or with primary CDI on concurrent antibiotics. Lack of strong quality evidence limits the use of probiotics in prevention of CDI. Clinical trials involving vaccines against *C. difficile* toxins, antitoxin immunoglobulin therapy, and use of non-toxigenic *C. difficile* strains are currently underway to evaluate its effectiveness in prevention of CDI. The efficacy of supplemental anti-CDI prophylaxis therapy (ribaxamase, DAV132) during antibiotic treatment of non-CDI related sepsis is being studied, with the goal to minimize antibiotic exposure and retain normal gut microbiota.

Among preventive therapies, treatment with monoclonal antibody against *C. difficile* toxin A and toxin B has been evaluated in clinical trials to prevent recurrent CDI. Even though actoxumab (antitoxin A monoclonal antibody) failed to demonstrate efficacy in prevention of recurrent disease, bezlotoxumab (antitoxin B monoclonal antibody) has shown promising results. A summary on current and emerging management options for CDI is illustrated in Table 1.

**Structure and mechanism of action**

Bezlotoxumab is a fully humanized IgG1/kappa monoclonal antibody of 148 kDa molecular weight. An experimental study was conducted to understand the structure of bezlotoxumab bound to the toxin B. In this study, Western blot, temperature-dependent fluorescence, hydrogen deuterium
## Table 1  Current and emerging treatment and preventive options in *Clostridium difficile* infection

<table>
<thead>
<tr>
<th>Antimicrobial/Non-antimicrobial agents</th>
<th>Recommended dosage and duration</th>
<th>Role in CDI</th>
<th>Current guidelines recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>SHEA-IDSA2 2010</td>
<td>ESCMID21 2014</td>
</tr>
<tr>
<td><strong>Current treatment options</strong></td>
<td></td>
<td></td>
<td>A-I</td>
<td>A-I</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>500 mg orally or intravenous thrice daily for 10–14 days</td>
<td>Initial episode, mild-moderate</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Initial episode, severe, complicated</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple recurrences</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>125 mg orally four times a day for 10–14 days</td>
<td>Initial episode, severe</td>
<td>B-I</td>
<td>A-I</td>
</tr>
<tr>
<td></td>
<td>500 mg orally four times a day for 10 days</td>
<td>Initial episode, severe or complicated</td>
<td>B-III</td>
<td>B-II</td>
</tr>
<tr>
<td>Vancomycin with metronidazole</td>
<td>500 mg orally or rectally (in ileus) four times a day with metronidazole intravenous 500 mg thrice daily</td>
<td>Initial episode, severe-complicated</td>
<td>C-III</td>
<td>A-II (metronidazole) B-III (vancomycin)</td>
</tr>
<tr>
<td>Fidaxomicin</td>
<td>200 mg orally twice daily for 10 days</td>
<td>Initial episode, mild-moderate</td>
<td>-</td>
<td>B-I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Initial episode, severe</td>
<td>-</td>
<td>B-I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Risk of) First recurrent episode</td>
<td>-</td>
<td>D-III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Life-threatening CDI Multiple recurrent episodes</td>
<td>-</td>
<td>B-II</td>
</tr>
<tr>
<td>Fecal microbiota transplant</td>
<td>Administered along with oral antibiotic therapy</td>
<td>Multiple recurrences</td>
<td>-</td>
<td>A-I</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>50 mg intravenous twice daily for 14 days</td>
<td>Severe episode</td>
<td>-</td>
<td>C-III</td>
</tr>
<tr>
<td>Nitazoxanide</td>
<td>500 mg oral twice daily for 10 days</td>
<td>Initial CDI</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rifaximin</td>
<td>400 mg oral twice daily for 10–14 days</td>
<td>Initial and recurrent CDI</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Teicoplanin</td>
<td>400 mg oral twice daily for 10 days</td>
<td>Initial CDI</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>20,000–25,000 units orally four times daily for 7–10 days</td>
<td>Initial CDI</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td>250 mg oral thrice daily for 7–10 days</td>
<td>Initial CDI</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tolevamer</td>
<td>3 g oral thrice daily</td>
<td>Initial CDI</td>
<td>-</td>
<td>D-I</td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Antimicrobial/Non-antimicrobial agents</th>
<th>Recommended dosage and duration</th>
<th>Role in CDI</th>
<th>Current guidelines recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current preventive options</strong></td>
<td></td>
<td></td>
<td>SHEA-IDSA&lt;sup&gt;2&lt;/sup&gt; 2010</td>
<td>ESCMID&lt;sup&gt;21&lt;/sup&gt; 2014</td>
</tr>
<tr>
<td>Bezlotoxumab</td>
<td>10 mg/kg intravenous single dose along with standard CDI antibiotic therapy</td>
<td>Prevention of recurrent CDI</td>
<td>-</td>
<td>C-I</td>
</tr>
<tr>
<td>Probiotics (Saccharomyces boulardii, Lactobacillus rhamnosus GG)</td>
<td>Initial and Recurrent CDI</td>
<td>-</td>
<td>D-I</td>
<td>Adjunct to the standard-of-care antibiotic therapy. Insufficient data to support its use in prevention of CDI. Risk of fungemia in critically-ill patients.</td>
</tr>
<tr>
<td><strong>Emerging treatment options</strong></td>
<td></td>
<td></td>
<td>SHEA-IDSA&lt;sup&gt;2&lt;/sup&gt; 2010</td>
<td>ESCMID&lt;sup&gt;21&lt;/sup&gt; 2014</td>
</tr>
<tr>
<td>Cadazolide</td>
<td>250 mg oral twice daily</td>
<td>Phase III trial</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Surotomycin</td>
<td>250 mg oral twice daily</td>
<td>Phase III trial (completed)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ridinilazole</td>
<td>250 mg oral twice daily</td>
<td>Phase II trial (completed)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SER-109 (encapsulated microbiota)</td>
<td>Orally administered</td>
<td>Phase II trial (completed)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>RBX2660 (microbiota suspension)</td>
<td>Enema suspension</td>
<td>Phase II trial</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Emerging preventive options</strong></td>
<td></td>
<td></td>
<td>SHEA-IDSA&lt;sup&gt;2&lt;/sup&gt; 2010</td>
<td>ESCMID&lt;sup&gt;21&lt;/sup&gt; 2014</td>
</tr>
<tr>
<td>Immunoglobulins</td>
<td>150–400 mg/kg</td>
<td>Initial and recurrent CDI</td>
<td>-</td>
<td>C-II (Initial CDI) D-I (Recurrent CDI)</td>
</tr>
<tr>
<td>Non-toxigenic C. difficile strains (VP 20621)</td>
<td>Phase II trial (completed)</td>
<td>-</td>
<td>-</td>
<td>Substitute toxigenic C. difficile to non-toxigenic form. Potential indication in prevention of recurrent CDI. Immunization to promote production of neutralizing antitoxin antibody for primary prevention of CDI.</td>
</tr>
<tr>
<td>Toxoid-based conjugated vaccines</td>
<td>Phase II/III (completed)</td>
<td>-</td>
<td>-</td>
<td>Protection of gut microbiota by prevention of antibiotic mediated gut microbiota dysbiosis. Data limited to the porcine gut model study. Potential indication as prophylactic treatment for prevention of CDI. Acts by binding and neutralizing antibiotics in the gut, retaining normal microbiota.</td>
</tr>
<tr>
<td>Ribaxamase</td>
<td>75 mg oral four times daily (dose per Phase II trial)</td>
<td>Phase II trial</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DAV-132</td>
<td>Phase I trial</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

*Note: Guidelines recommendation to support use: A- Strong evidence, B- Moderate evidence, C- Marginal evidence, D- No evidence. Abbreviations: CDI, Clostridium difficile infection; ESCMID, European Society of Clinical Microbiology and Infectious Diseases; FDA, US Food and Drug Administration; IDSA, Infectious Diseases Society of America; SHEA, Society for Healthcare Epidemiology of America.*

exchange-mass spectrometry, and surface plasmon resonance tests confirmed the interaction of bezlotoxumab with the intact full-length of C. difficile toxin B and its peptides. X-ray crystallography demonstrated Fab fragments of bezlotoxumab binding specifically to two epitopes within the N-terminal half of oligopeptide domains of toxin B. The binding results in complete neutralization of toxin B by directly blocking its carbohydrate binding pockets and
thus preventing its attachment to the colonic mucosal cells. Other postulated mechanisms of neutralization of toxin B by bezlotoxumab include conformational change in toxin B masking its receptor binding sites, blocking cell adhesion via binding to alternative non-carbohydrate binding pockets. Bezlotoxumab showed no binding affinity to toxin A.

Bezlotoxumab is administered via intravenous route and animal studies have provided insight into the mechanism of antibody transport into the gut epithelium. Contrary to the previous belief, a study on murine and hamster models infected with C. difficile showed Fc receptor independent transport of antibodies into the gut epithelium. Consequently, an in vitro study performed on intestinal mucosal epithelium simulation model reinforced Fc independent paracellular transport of Fab fragments of antitoxin antibodies across the gut. The antibody transport was seen to be directly proportional to the presence of toxins in apical chamber of the intestinal epithelial cells. Thus, confirming that toxin-mediated intestinal epithelial damage promotes the transport of antitoxin antibodies into the intestinal lumen.

**Pharmacokinetics (PK) and pharmacodynamics (PD)**

Bezlotoxumab is administered as a single 10 mg/kg intravenous dose infused over 60 minutes for the prevention of recurrent CDI. Each vial contains 1000 mg of sterile, aqueous, preservative-free bezlotoxumab, diluted in 0.9% sodium chloride or 5% dextrose prior to infusion. Bezlotoxumab is approved for use only in the adult (≥18 years of age) population while on concomitant anti-CDI therapy and has been approved for use only in the adult (≥18 years of age) group. Bezlotoxumab was generally administered an average of 3 days from the standard-of-care treatment. The dosing is based on the actual body weight. No dose adjustment is required in presence of hepatic impairment or renal dysfunction. The pharmacokinetic study showed the lack of effect of different population demographics (age, gender, race, albumin level, comorbidities) on effective concentration of bezlotoxumab. Administration of bezlotoxumab along with standard-of-care CDI therapy has no effect on its efficacy. Bezlotoxumab has a mean volume of distribution of 7.33 L and achieves a maximum concentration of 185 μg/mL. In the Phase II trials, patients in the monoclonal antibody group had detectable levels of antitoxin B in the serum for 22±13 days, after the initial infusion. Bezlotoxumab has an estimated long half-life of 19 days in humans with clearance at a rate of 0.317 L/day. It is cleared by protein catabolism into smaller peptides and amino acids. It is cleared rapidly in individuals with higher body weight. Bezlotoxumab acts directly on the toxin B and does not alter any metabolic enzymes or transporters. There is no in vivo or in vitro evidence of any drug–drug interactions or any teratogenic potential of bezlotoxumab.

Higher concentration of bezlotoxumab was seen in the toxin-damaged intestinal lumen of C. difficile infected hamster models compared to controls. The PK/PD relationship remains undetermined due to inability to quantify the precise concentration of bezlotoxumab in the serum or stool specimens. The required concentration of bezlotoxumab in the gut lumen to effectively inactivate toxin B is also unknown.

**Efficacy studies**

**Animal studies**

In vivo studies were performed in various animal models to evaluate the effectiveness of monotherapy or combination therapy of monoclonal antibodies against CDI. The results of these studies provided guidance in dosing and treatment strategy to perform future clinical trials in humans.

Studies conducted in animal models established the protective mechanism of antitoxin antibodies against CDI independent of its host effector functions. A study conducted on murine models showed significantly lower intestinal epithelial cell wall damage, hemorrhage, necrosis, infiltration with neutrophils and apoptotic cells in models treated with combined monoclonal antibodies (actoxumab–bezlotoxumab) compared to untreated models. The antibodies were also deemed to provide indirect protection to the colonic wall by negating toxin-mediated damage. Unlike the currently available therapies for CDI, antitoxin antibodies demonstrated similar neutralization and protective mechanism of action against the hypervirulent (NAP1/BI/027) C. difficile strains.

Hamsters are the standard models used for in vivo analysis during the study of CDI. Hamsters develop severe CDI as compared to humans but its therapeutic response to treatment serves it as a suitable model for analysis. Babcock et al conducted two experiments on hamster models to demonstrate the efficacy of monoclonal antitoxin antibodies in CDI. The initial study was performed to assess the mortality benefit in hamster model with primary CDI. Primary CDI was induced in the hamster models by administration of clindamycin at least 24 hours prior to the orogastric instillation of C. difficile spores. Intraperitoneal administration of antitoxin A antibody (50 mg/kg/day) and antitoxin B antibody (10–50 mg/kg/day)
alone or as a combination therapy was performed for 4 days prior to the administration of *C. difficile* spores. Traditionally without antitoxin antibodies, 100% mortality was seen in all the hamster models due to severe CDI. The study showed 45% reduction in mortality in the hamster models treated with combination monoclonal antibodies. In the second part of the study, the efficacy of antitoxin antibodies was evaluated in the hamster models with relapse of CDI. Hamster models with CDI relapse were challenged with *C. difficile* spores and simultaneously initiated on vancomycin treatment. In the study, models received either vancomycin alone or in combination with monoclonal antitoxin antibody A or B or both A and B from day 2–6 post-spore challenge. In comparison to vancomycin monotherapy, treatment with vancomycin and combination monoclonal antibodies demonstrated early (day 6) and late (day 10) protection against mortality from CDI. The early and late survival rates in the hamster models increased by 38% and 22%, respectively. In both primary and relapse models of CDI, treatment with antitoxin B monoclonal antibody alone did not show any survival benefit. Based on quantitative analysis of protective monoclonal antibody levels in the hamster sera, administration of a single dose of 10 mg/kg of monoclonal antibodies was recommended in the management of CDI in humans.

A similar in vivo study was performed by Dzunkova et al in mice models infected with CDI. Mice models were initially treated with clindamycin, then treated with vancomycin antibiotic and/or monoclonal antibodies followed by inoculation with *C. difficile* spores. Models were divided into four treatment groups; combination therapy alone (actoxumab–bezlotoxumab), combination of monoclonal antibodies and vancomycin, vancomycin alone, and placebo. Mice models with severe CDI were followed until end of the study (day 28). An 80% survival rate was seen in the mice models that received combination of vancomycin and monoclonal antibodies. Treatment group receiving only actoxumab–bezlotoxumab showed 90% reduction in CDI symptoms during the entire study period. On the contrary, the mice models treated with vancomycin alone had mortality of 60% and placebo group had 100% mortality by day 4 of the study period. Further intestinal microbial diversity analysis in mice models elucidated distinct characteristic of monoclonal antibodies to help restore the original gut microbiota, not observed with vancomycin treatment.

A comparative study was conducted in hamster and mice CDI-infected models to evaluate the effectiveness of vancomycin and monoclonal antibodies in prevention of recurrent CDI. The study showed functionality of vancomycin against CDI to be limited to the duration of therapy. Vancomycin was associated with simultaneous damage to the gut microbiota resulting in a delayed recovery and higher predisposition to CDI recurrence. Monoclonal antibodies preserved the gut microbiota and were postulated to neutralize the toxin release from new as well as persistent *C. difficile* spores, demonstrating its potency in prevention of recurrent CDI.

**Human studies**

Phase I trial: a total of five Phase I trials were conducted to assess the effects of monoclonal antibodies in healthy subjects. All the trials included administration of bezlotoxumab as monotherapy or as part of combination therapy except one trial. Only four trials of interest are discussed in this section.

A Phase I dose escalation study (P020) was performed enrolling 60 healthy adult volunteers; six received actoxumab, 30 received bezlotoxumab, and 24 received combination of monoclonal antibodies. This was the only Phase I study to evaluate independent bezlotoxumab PK after administration of ascending drug doses ranging from 0.3 to 20 mg/kg. Unfortunately, the non-specific bioanalytical assay used in the study failed to distinguish between the endogenous antitoxin B antibodies and bezlotoxumab. Thus, due to lack of validity, the PK and immunogenicity analysis from this study were not taken into consideration.

A Phase I open-label multi-dose study (P004) was conducted to evaluate the PK and immunogenicity analysis of monoclonal antibodies against toxin A and B in healthy adults. A total of 30 subjects were included receiving initial 10 mg/kg dose of actoxumab and bezlotoxumab as a 1-hour infusion, followed by repeat second dose on day 85. Another Phase I double-blind, randomized placebo-controlled single dose study (P005) was performed in 35 healthy adult subjects. Subjects received a 10 mg/kg dose of actoxumab and bezlotoxumab over 1-hour infusion. Pharmacokinetic analysis was performed in 23 subjects on day 22 and 12 subjects on day 85. This was the primary study to evaluate the PK and tolerability of monoclonal antibodies administered as a 250 mL infusion over 1-hour duration. Similar to other Phase I trials, a double-blind, randomized placebo-controlled trial (P006) was conducted in 19 healthy Japanese male volunteers. Subjects were administered a single dose of actoxumab and bezlotoxumab at 10 or 20 mg/kg dose in a 250 mL infusion.

The results of all four Phase I trials showed bezlotoxumab to be a safe and well-tolerated drug when infused as monotherapy or combination therapy. No serious adverse events were seen in the healthy volunteers. The PK analysis showed
similar parameters in the Japanese and the non-Japanese volunteers. The drug clearance was independent of administered dose. Immunogenicity analysis in the trials did not detect any serum anti-bezlotoxumab antibodies. The Phase I studies identified pharmacokinetic characteristics of bezlotoxumab to be similar to other monoclonal antibodies and established 10 mg/kg as the recommended infusion dosage.

Phase II trial: a Phase II randomized double-blind placebo-controlled trial was conducted across multiple centers in the USA and Canada. The trial enrolled CDI patients with ongoing diarrhea while on vancomycin or metronidazole treatment. Patients were randomized to receive either a single intravenous infusion of 10 mg/kg of fully human monoclonal antibody against C. difficile toxin A (CDA1) and toxin B (CDB1) or placebo. A total of 200 patients were included in the study, 101 in monoclonal antibody group and 99 in placebo group. Patients received an average of 3 days of antibiotic therapy (70% on metronidazole and 30% on vancomycin) prior to enrollment in both groups. Overall, patients in the monoclonal antibody group had significantly lower CDI recurrence rate (7%) compared to placebo group (25%), at the end of antibiotic therapy or after resolution of diarrhea. The subjects with recurrent CDI in the monoclonal antibody group were known to be at high risk for recurrence (old age and higher comorbidities) during enrollment. No differences were observed in the hospital length of stay and time to diarrhea resolution in both groups.

Phase III trial: two Phase III randomized placebo-controlled trials were conducted across the globe to analyze the effect of administering specific monoclonal antibodies and combined monoclonal antibodies in patients with CDI. A total of 2599 patients with CDI on treatment with vancomycin (48%) or metronidazole (47%) or fidaxomicin (4%) were included in the study. Patients were randomized to receive either a single intravenous infusion of bezlotoxumab (773), actoxumab–bezlotoxumab (773), actoxumab alone (232) or placebo (773). The study results showed significantly lower rates of CDI recurrence in the bezlotoxumab group (17%) and combination monoclonal antibodies group (15%) compared to placebo (27%). The initial cure rate was similar in the bezlotoxumab (80%), bezlotoxumab–actoxumab (73%) and placebo groups (80%) and the sustained cure rates at the end of 12 weeks were slightly higher in bezlotoxumab arm (64%) compared to placebo (54%). The majority of the recurrences (71%) occurred within the first month after monoclonal antibody infusion. The choice of antibiotic therapy for treatment of CDI did not influence the treatment outcomes in both groups. The CDI recurrence rate in the study groups was similar in patients of different geographic locations and independent of hospitalization status during the enrollment.

High-risk population

The Phase II and III trials analyzed the effect of bezlotoxumab in a population at high risk of recurrent CDI such as those with presence of previous history of CDI and BI/NAP1/027 strain.

In a Phase II trial, 31% of the population had a previous history of CDI and treatment with combination monoclonal antibodies resulting in significantly lower rate of recurrence (7%) compared to placebo (38%). Likewise, in a Phase III trial, in patients with one or more risk factors for CDI (77%), treatment with bezlotoxumab showed lower rates of CDI recurrence compared to placebo (17% vs 30%).

An in vitro study on Vero cells showed lower binding affinity of bezlotoxumab to toxin B of ribotypes 027 and 078 in comparison to other ribotypes. Administration of a higher than normal concentration of bezlotoxumab was required to neutralize toxin B of these hypervirulent ribotype strains. Approximately 29% of patients enrolled in the Phase II trial had detectable epidemic BI/NAP1/027 strain. Treatment of epidemic strain with combination monoclonal antibodies resulted in lower recurrence rate (8%) compared to placebo (32%), however the difference failed to achieve statistical significance (p=0.06). In the Phase III trial, the 027 strain of C. difficile was present in 18% of patients. Treatment with combination monoclonal antibodies had higher impact in decreasing the risk of recurrent CDI in comparison to bezlotoxumab alone or placebo (12% vs 24% vs 34% recurrence). Overall, in the Phase III trial, patients at high risk of recurrent CDI or adverse outcomes from CDI had lower recurrence rates in the bezlotoxumab (17%) and actoxumab–bezlotoxumab (16%) group compared to placebo (30%).

Indication and approval

Based on Phase III clinical trial results, the US Food and Drug administration (FDA) approved the use of bezlotoxumab in prevention of recurrent CDI in October 2016. Bezlotoxumab is indicated for use in adult patients (≥18 years of age) at high risk of recurrence, undergoing the standard-of-care antimicrobial treatment for CDI. Patients with CDI in the previous 6 months, severe CDI, aged ≥65 years, ongoing antibacterial therapy, immunocompromising conditions and CDI due to hypervirulent ribotype strains 027, 078 or 244 were defined to be at high risk for recurrence. Bezlotoxumab is not approved for use in the clinical cure of CDI.
Resistance
Currently, there is no evidence on development of resistance to bezlotoxumab. The Phase II and III randomized trials performed serum studies to detect anti-bezlotoxumab antibodies. Both the trials showed no detectable anti-monomoclonal antibody levels.\(^3\) In addition, in vitro studies also did not demonstrate any evidence of anti-bezlotoxumab antibody production.

Safety and precautions
Studies exclusively analyzing the safety and efficacy of bezlotoxumab have not been conducted. Most of the adverse events related to bezlotoxumab are based on reports from the Phase II and III randomized controlled trials.\(^2\) Overall, the adverse events secondary to monoclonal antibody therapy were non-serious and did not differ compared to placebo. Infusion-related reactions were usually mild. In the Phase III trial, possible acute hypersensitivity reaction on the same day or a day after infusion was reported in 10% (81/786) of the participants receiving bezlotoxumab compared to 7.6% (59/781) receiving placebo. During the follow-up period, nausea, diarrhea, and headache were the most common adverse events reported. Serious adverse events were rare with no significant difference between treatment and placebo arm, except for significantly higher hypotension events in the placebo group in the Phase II trial. There was no difference in the 3-month mortality incidences in both groups.

There was no effect of bezlotoxumab on QTc interval. Precaution is advised prior to usage of bezlotoxumab in patients with heart failure.\(^3\) The Phase III clinical trials reported higher adverse events in patients with preexisting congestive heart failure (CHF) in bezlotoxumab treatment arm. During the 12-week study period, higher CHF and deaths occurred in bezlotoxumab (CHF 13%, death 19.5%) arm compared to the placebo arm (CHF 5%, death 12.5%). Bezlotoxumab should be used cautiously in patients with underlying CHF, use is advised only when the benefit outweighs risk.

Toxicology studies conducted on mice did not demonstrate any clinical or histological evidence of toxicity related to bezlotoxumab in comparison to placebo, even at higher than recommended concentrations.\(^3\)

Cost-estimate
A single 100 mg vial of bezlotoxumab costs US$4,500.\(^4\) An unpublished post hoc analysis on bezlotoxumab showed lower 30-day CDI-related hospital readmissions (4% with bezlotoxumab vs 9.6% with placebo) as well as all-cause readmissions (23% with bezlotoxumab vs 26.9% with placebo).\(^5\) No published studies have been conducted to analyze the cost-effectiveness of administering bezlotoxumab along with anti-CDI therapy.

Uncertainties and future perspectives
Bezlotoxumab is the first FDA-approved monoclonal antibody active against \emph{C. difficile} toxin B. All the in vivo, in vitro human and animal research studies have established its effectiveness in the prevention of recurrent CDI. Numerous uncertainties challenge the clinical use of bezlotoxumab. The rising health care expenditure and lack of evidence on the pharmacoeconomic benefits of addition of bezlotoxumab to the standard anti-CDI therapy might be the limiting factor for the real-time usage of this high-cost drug. Universal approval of any drug in management of disease relies profoundly on strong recommendations in the standard guidelines. The level of recommendation for bezlotoxumab as a preventive therapy option in the USA and the European CDI guidelines is currently unknown. Numerous antibiotic therapies (suroto-mycin, cadazolid) and prophylactic agents (immunoglobulin vaccines, biologic agents) against CDI are currently in the pipeline, challenging the shelf-life of bezlotoxumab. Table 2 highlights the important benefits and risks associated with bezlotoxumab.

### Table 2

<table>
<thead>
<tr>
<th>Advantages/benefits</th>
<th>Disadvantages/risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Approved for use in prevention of recurrent CDI</td>
<td>1. No efficacy in clinical cure of CDI</td>
</tr>
<tr>
<td>2. One-time dose administration</td>
<td>2. Requires intravenous administration</td>
</tr>
<tr>
<td>3. Restores gut microbiota</td>
<td>3. Lack of specific time-interval for infusion in correlation to the standard-of-care CDI therapy</td>
</tr>
<tr>
<td>4. Effective against geographically diverse \emph{C. difficile} strains and against hypervirulent strain of \emph{C. difficile} (BI/NAP1/027)</td>
<td>4. Unknown serum target levels to achieve effective intestinal luminal concentration against antitoxin B</td>
</tr>
<tr>
<td>5. No need for dose adjustment, lacks drug-drug interaction</td>
<td>5. Limited data on effectiveness as monotherapy in prevention of CDI</td>
</tr>
<tr>
<td>6. Minimal serious adverse events</td>
<td>6. High-cost drug with no data on cost-effectiveness</td>
</tr>
<tr>
<td>7. No evidence of resistance to treatment</td>
<td>7. No published data on real-world experience to validate its efficacy</td>
</tr>
</tbody>
</table>

Abbreviation: CDI, \emph{Clostridium difficile} infection.
Conclusion
Bezlotoxumab is an effective monoclonal antibody against C. difficile toxin B reducing recurrent CDI by 40% at the end of 12 weeks in comparison to placebo. A single infusion of safe and well-tolerated bezlotoxumab is easy to administer, however cost-effectiveness analysis has not been performed yet to validate usage of this high-priced drug. In the era of finite choices for treatment of recurrent CDI, bezlotoxumab emerges as a compelling rescue therapy for prevention of recurrent CDI. Further data are needed to establish its clinical effectiveness.

Disclosure
The authors report no conflicts of interest in this work.

References